MOLECULAR SCREENING IN ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES FOR FIRST-LINE THERAPY

被引：0
|
作者：
Zaim, Remziye [1 ]
Thunnissen, Erik [2 ]
Dingemans, Anne-Marie [3 ]
Postmus, Pieter E. [2 ]
Uyl-De Groot, Carin A. [1 ]
机构：
[1] Erasmus Univ, NL-3000 DR Rotterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[3] Maastricht Univ, Med Ctr, Maastricht, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
advanced non-small cell lung cancer; molecular screening; cost-effective; systematic review;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-023
引用
收藏
页码：S604 / S605
页数：2
相关论文
共 50 条
  • [31] Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review
    Thitima Kongnakorn
    Grammati Sarri
    Andreas Freitag
    Kinga Marczell
    Paulina Kazmierska
    Elizabeth Masters
    Vivek Pawar
    Xinke Zhang
    [J]. PharmacoEconomics, 2022, 40 : 183 - 201
  • [32] Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review
    Kongnakorn, Thitima
    Sarri, Grammati
    Freitag, Andreas
    Marczell, Kinga
    Kazmierska, Paulina
    Masters, Elizabeth
    Pawar, Vivek
    Zhang, Xinke
    [J]. PHARMACOECONOMICS, 2022, 40 (02) : 183 - 201
  • [33] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong, Thomas
    Morgensztern, Daniel
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
  • [34] Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
    Mo, Xiuting
    Moriwaki, Kensuke
    Morimoto, Kosuke
    Shimozuma, Kojiro
    [J]. CLINICAL DRUG INVESTIGATION, 2022, 42 (07) : 599 - 609
  • [35] Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
    Xiuting Mo
    Kensuke Moriwaki
    Kosuke Morimoto
    Kojiro Shimozuma
    [J]. Clinical Drug Investigation, 2022, 42 : 599 - 609
  • [36] OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA
    Zhou, J.
    Jiang, G.
    [J]. VALUE IN HEALTH, 2020, 23 : S54 - S54
  • [37] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S165 - S166
  • [38] Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
    Khan, Iftekhar
    Morris, Stephen
    Hackshaw, Allan
    Lee, Siow-Ming
    [J]. BMJ OPEN, 2015, 5 (07):
  • [39] Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States
    Criss, Steven D.
    Mooradian, Meghan J.
    Watson, Tina R.
    Gainor, Justin F.
    Reynolds, Kerry L.
    Kong, Chung Yin
    [J]. JAMA NETWORK OPEN, 2019, 2 (09)
  • [40] A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
    Cuc Thi Thu Nguyen
    Fabio Petrelli
    Stefania Scuri
    Binh Thanh Nguyen
    Iolanda Grappasonni
    [J]. The European Journal of Health Economics, 2019, 20 : 763 - 777
12345